TELA Bio (TELA) Stock Price, News & Analysis

Company Overview

TELA Bio, Inc. is a clinical-stage regenerative medicine company focused on the development and commercialization of next‐generation biomaterial therapies designed to improve the repair of soft tissue across multiple surgical specialties. The company’s proprietary platform combines biologically derived materials with synthetic polymer reinforcement to create a family of hybrid tissue repair products that are intended to support tissue regeneration, restore functional integrity and reduce complications associated with existing repair solutions.

The company’s lead portfolio centers on the OviTex® line of soft tissue repair products. These mesh-like scaffolds utilize a unique interwoven design of decellularized ovine extracellular matrix and permanent or resorbable polymer fibers, offering strength, biocompatibility and the potential for cellular in‐growth. OviTex products are used primarily in hernia repair and abdominal wall reconstruction, with ongoing development programs targeting orthopedic soft tissue applications, sports medicine and general surgical procedures.

Founded in 2016 and headquartered in Malvern, Pennsylvania, TELA Bio completed its initial public offering in mid-2021 and has since expanded its commercial footprint across the United States and select international markets. The company leverages a direct sales force, strategic distribution partnerships and clinical collaborations to support adoption of its regenerative technologies. TELA Bio continues to advance its research pipeline through preclinical and clinical studies aimed at broadening indications and optimizing scaffold designs for various tissue repair needs.

Under the leadership of Chief Executive Officer Craig Singhaus and a management team with deep experience in medical device innovation and commercialization, TELA Bio is committed to transforming soft tissue repair by delivering biomaterial therapies that address unmet clinical needs. The company maintains a collaborative environment with key opinion leaders and academic institutions to drive scientific validation and expand the evidence base for its product platform.

Key Stats

• Today's Range: $1.99 to $2.10
• 50-Day Range: $0.95 to $2.14
• 52-Week Range: $0.86 to $4.86
• Volume: 24,592 shs
• Average Volume: 204,891 shs
• Market Capitalization: $79.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.25
• Consensus Rating: Moderate Buy

TELA Bio Stock Analysis - MarketRank™

TELA Bio scored higher than 57% of companies evaluated by MarketBeat, and ranked 474th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

TELA Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

TELA Bio has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for TELA Bio are expected to grow in the coming year, from ($1.37) to ($0.66) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TELA Bio is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of TELA Bio is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

TELA Bio has a P/B Ratio of 2.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.34% of the float of TELA Bio has been sold short.

Short Interest Ratio / Days to Cover

TELA Bio has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in TELA Bio has recently decreased by 11.11%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TELA Bio does not currently pay a dividend.

Dividend Growth

TELA Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.34% of the float of TELA Bio has been sold short.

Short Interest Ratio / Days to Cover

TELA Bio has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in TELA Bio has recently decreased by 11.11%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: N/A

News Sentiment

TELA Bio has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for TELA Bio this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TELA Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.70% of the stock of TELA Bio is held by insiders.

Percentage Held by Institutions

94.35% of the stock of TELA Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TELA Stock Analysis - Frequently Asked Questions

How have TELA shares performed this year?

TELA Bio's stock was trading at $3.02 at the beginning of the year. Since then, TELA stock has decreased by 33.4% and is now trading at $2.01.

How were TELA Bio's earnings last quarter?

TELA Bio, Inc. (NASDAQ:TELA) announced its earnings results on Thursday, May, 8th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.04. The firm had revenue of $18.52 million for the quarter, compared to analyst estimates of $17.35 million. TELA Bio had a negative net margin of 61.00% and a negative trailing twelve-month return on equity of 402.45%.
Read the conference call transcript.

When did TELA Bio IPO?

TELA Bio (TELA) raised $60 million in an initial public offering on Friday, November 8th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

How do I buy shares of TELA Bio?

Shares of TELA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TELA Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TELA Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Chevron (CVX).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/16/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:TELA
• CIK: 1561921
• Web: www.telabio.com
• Phone: 484-320-2930
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for TELA Bio: $7.25
• High Price Target: $12.00
• Low Price Target: $2.00
• Potential Upside/Downside: +260.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$37.84 million
• Net Margins: -61.00%
• Pretax Margin: -61.13%
• Return on Equity: -402.45%
• Return on Assets: -62.73%

Debt

• Debt-to-Equity Ratio: 2.28
• Current Ratio: 4.22
• Quick Ratio: 3.40

Sales & Book Value

• Annual Sales: $69.30 million
• Price / Sales: 1.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.72 per share
• Price / Book: 2.79

Miscellaneous

• Outstanding Shares: 39,560,000
• Free Float: 37,696,000
• Market Cap: $79.52 million
• Optionable: Optionable
• Beta: 0.90